Reactions 1680, p102 - 2 Dec 2017
Vitiligo: case report
A woman in her 50s [exact age at reaction onset not stated]
developed vitiligo during treatment with cyclophosphamide,
doxorubicin [adriamycin] and paclitaxel.
The woman had a history of hypothyroidism treated with
thyroxine replacement therapy. She was diagnosed with breast
cancer along with an axillary lymphadenopathy at the age of
58 years, and underwent left modified radical mastectomy.
Subsequently, she received 4 cycles of chemotherapy with
cyclophosphamide 600 mg/m
and doxorubicin 60 mg/m
followed by four cycles of paclitaxel 175 mg/m
stated]. After completion of 24 week chemotherapy course,
she was treated with an external beam radiotherapy to the left
chest wall. Approximately nine months after radiotherapy, she
was observed with a depigmentation on the left chest wall,
which was congruent with area of radiation delivery. The
hypopigmented lesions could be identified with sharp
margins. The lesions were without a definite shape, which
coalesced and persisted as evidenced in her successive follow-
At the last follow up, the woman was found to be well,
though continued with hypopigmented lesions on the left
chest, without any further regression or progression.
Author comment: "It is not clear whether addition of
chemotherapy contributed to the development of
hypopigmentation, but it was likely a risk factor."
Pavithran K, et al. Report of a case of radiation-induced new-onset vitiligo with
collective review of cases in the literature of radiation-related vitiligo. Case
Reports in Medicine 2013: 2013. Available from: URL: http://
doi.org/10.1155/2013/345473 - India
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved